References
- Christophers E. Psoriasis‐epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314–20
- Wong K., Gladman D. D., Husted J., Long J. A., Farewell V. T. Mortality studies in psoriatic arthritis: Results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997; 40: 1868–72
- Koo J. Population‐based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485–96
- Krueger G. G., Koo J., Lebwohl M., Menter A., Stern R. S., Rolstad T. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient‐membership survey. Arch Dermatol 2001; 137: 280–4
- Roenigk H. H., Jr., Auerbach R., Maibach H., Weinstein G., Lebwohl M. Methotrexate in psoriasis: Consensus conference. J Am Acad Dermatol 1998; 38: 479–85
- Spadaro A., Taccari E., Mohtadi B., Riccieri V., Sensi F., Zoppini A. Life‐table analysis of cyclosporin A treatment in psoriatic arthritis: Comparison with other disease‐modifying antirheumatic drugs. Clin Exp Rheumatol 1997; 15: 609–14
- Ortonne J. ‐P. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999; 140: 1–7
- Gaspari A., Gottlieb A. B., Kang S. Etanercept improves the clinical and pathological features of psoriasis. Presented at the Society for Investigative Dermatology. 2002
- Mease P. J., Kivitz A. J., Burch F. X., Siegel E. L., Cohen S. B., Ory P., et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2269–72
- Costanzo A., Mazzotta A., Papoutsaki M., Nistico S., Chimenti S. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 2005; 152: 187–9
- Mease P., Goffe B., Metz J., Vanderstoep A. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000; 356: 385–90
- Gottlieb A. B. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17: 401–8
- Lebwohl M. G., Gottlieb A. B., Wallis W. J., Zitnik R. J. Global safety and efficacy of more than five years of etanercept (Enbrel) therapy in rheumatoid arthritis. Presented at the American Academy of Dermatology 62nd Annual Meeting;, Washington, DC, 2004, poster P550
- Greaves M. W., Weinstein G. D. Drug therapy: Treatment of psoriasis. N Engl J Med 1995; 332: 581–8
- De Vlam K., Lories R. J. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: A 26‐week observational study. Rheumatology (Oxford) 2006; 45: 321–4, Epub 2005 Oct 18